Ki-67 labeling index is associated with recurrence after segmentectomy under video-assisted thoracoscopic surgery in stage I non-small cell lung cancer

Ann Thorac Cardiovasc Surg. 2011;17(4):341-6. doi: 10.5761/atcs.oa.10.01573.

Abstract

Objectives: Video-assisted thoracoscopic surgery (VATS) segmentectomy for small or early stage non-small cell lung cancer (NSCLC) remains controversial. Here, we investigated the clinical importance of predicting recurrence by Ki-67 in VATS segmentectomy for stage I NSCLC.

Methods: In a retrospective study, 44 consecutive patients in p-stage I underwent VATS segmentectomy between September 2003 and April 2009. After clinicopathological factors were compared with Ki-67 expression, the relationship between Ki-67 labeling indexes (LI) or mRNA expression by quantitative RT-PCR and prognosis was investigated.

Results: Five of 44 VATS segmentectomy patients relapsed. In the relapsed patients, 3 (6.8%) were local recurrences and 2 (4.5%) were distant metastases. There was no significant difference between clinicopathological factors and recurrence; however, patients with Ki-67 LI less than 5% showed better disease-free survival than patients with Ki-67 LI over 5% (p = 0.04). In multivariate Cox regression analysis, although there was no significantly different in disease-free survival by age, histology, tumor size, only Ki-67 LI showed a significant prognostic factor of recurrence (HR = 12.5, 95% CI = [1.1-1407], p = 0.04).

Conclusions: Ki-67 LI after VATS segmentectomy was a prognostic factor of disease-free survival in NSCLC and the treatment of choice for patients with positive LI may be considered, in addition to adjuvant chemotherapy, or lobectomy.

MeSH terms

  • Aged
  • Carcinoma, Non-Small-Cell Lung / chemistry
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / secondary
  • Carcinoma, Non-Small-Cell Lung / surgery*
  • Chi-Square Distribution
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry
  • Japan
  • Kaplan-Meier Estimate
  • Ki-67 Antigen / analysis*
  • Ki-67 Antigen / genetics
  • Lung Neoplasms / chemistry
  • Lung Neoplasms / genetics
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / surgery*
  • Male
  • Neoplasm Recurrence, Local*
  • Neoplasm Staging
  • Patient Selection
  • Pneumonectomy / adverse effects
  • Pneumonectomy / methods*
  • Pneumonectomy / mortality
  • Polymerase Chain Reaction
  • Proportional Hazards Models
  • RNA, Messenger / analysis
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Survival Rate
  • Thoracic Surgery, Video-Assisted* / adverse effects
  • Thoracic Surgery, Video-Assisted* / mortality
  • Time Factors
  • Treatment Outcome

Substances

  • Ki-67 Antigen
  • RNA, Messenger